Send to

Choose Destination
Oncotarget. 2016 Dec 25;8(32):52457-52464. doi: 10.18632/oncotarget.14199. eCollection 2017 Aug 8.

Prognostic role of podocalyxin-like protein expression in various cancers: A systematic review and meta-analysis.

Author information

Department of Hepatobiliary Disease, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
School of Medicine, Tongji University, Shanghai, China.
Department of General Surgery, 302 Hospital of PLA, Beijing, China.
Contributed equally


Several studies were conducted to explore the prognostic significance of podocalyxin-like protein (PODXL) expression in various cancers, with contradictory. This study aims to summarize the prognostic significance of PODXL expression in cancers. PubMed, the Cochrane Library and Embase were completely retrieved. The prospective or retrospective studies focusing on the prognostic role of PODXL expression in cancers were eligible. The endpoints were overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS).12 studies involving a total of 5,309 patients were identified. The results indicated that high PODXL expression was significantly associated with worse OS when compared to the low PODXL expression (HR=1.76, 95%CI=1.53-2.04, p<0.00001; I2=41%, p=0.08). And similar results were detected in the subgroup analysis of analysis model, ethnicity, sample size, tumor type and antibody type. And the results also showed that high PODXL expression was obviously related to shorter DSS (HR=2.47, 95%CI=1.53-3.99, p=0.0002; I2=66%, p=0.03) and DFS (HR=2.12, 95%CI=1.58-2.85, p<0.00001; I2=19%, p=0.29). In conclusion, it was revealed that high PODXL expression is an unfavorable predictor of OS, DSS and DFS in patients with cancers, and high PODXL expression is a promising prognostic biomarker for cancers, especially for patients in European.


cancer; overall survival; podocalyxin-like protein; prognostic

Conflict of interest statement

CONFLICTS OF INTEREST The authors have declared no conflicts of interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center